US FDA approves Tembexa: the first smallpox for all ages...

Chimerix recently announced that the US Food and Drug Administration (FDA) has approved Tembexa (brincidofovir) tablets and oral suspensions for the treatment of smallpox

Tembexa is a lipid conjugate of nucleotide analogues, designed to simulate natural monoacyl phospholipids to achieve an effective intracellular concentration of antiviral active metabolite cidofovir diphosphate (cidofovir diphosphate)

The FDA approved Tembexa, based on the efficacy data of two lethal orthopox virus animal models of human smallpox disease, namely the rabbitpox model (New Zealand white rabbits infected with rabbitpox virus) and the mousepox model (BALB/c infected with mousepox virus) Mice)

The FDA's "Animal Rules" allow testing of experimental drugs in animal models to support the effectiveness of diseases that are not ethical or suitable for human research

Smallpox is a highly contagious disease caused by the smallpox virus

Smallpox virus is one of the most complicated viruses, with double-stranded DNA genome, brick-shaped virus particles, and a very small amount of virus can cause infection

The molecular structure of brincidofovir (picture source: Wikipedia)

The active pharmaceutical ingredient of Tembexa is brincidofovir, which is a nucleotide analogue that has antiviral activity against all five DNA virus families that affect humans, including adenovirus and variola virus, the latter can cause smallpox

brincidofovir uses Chimerix's lipid conjugation technology and compound library discovery with independent intellectual property rights

Since 2011, Chimerix has been cooperating with the U.

Original source:

Chimerix Receives US Food and Drug Administration approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

This article is from Bio Valley, for more information, please download the Bio Valley APP (http://